Global Impetigo Therapeutic Market, By Treatment (Cephalosporins, Fusidane, Lincosamide, Penicillin, Penicillin-Like Antibiotics, Others), Route of Administration (Oral, Inhalation, Intranasal, Others), End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
Impetigo Therapeutic Market Analysis and Size
The global impetigo therapeutic market is expected to witness significant growth during the forecast period. Impetigo appears as red scores and bumps blister on face, particularly around nose and mouth, hands and feet. Impetigo is a global disease that affects about 162 million globally. Major focus is on product improvement and the development of advanced ointments, lotions and pills, which will cure the disease faster. Several latest medications restrict the reoccurrence of disease and improve the appearance of marks. Humidity and heat coupled with eczema develops the infection. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global impetigo therapeutic market in the forecast period 2022-2029. The global dilated cardiomyopathy market is tend to have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Impetigo Therapeutic Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Cephalosporins, Fusidane, Lincosamide, Penicillin, Penicillin-Like Antibiotics, Others), Route of Administration (Oral, Inhalation, Intranasal, Others),End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Alexion Pharmaceuticals, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Amgen Inc. (U.S.), Jazz Pharmaceuticals, Inc. (U.K.), Pfizer Inc (U.S.), PerkinElmer Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Abbvie Inc. (U.S.), Zydus Group (India), Wockhardt (India), Lannett (U.S.), Sun Pharmaceuticals Industries Ltd. (India), Amneal Pharmaceuticals LLC. (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Impetigo is also known as school sores, a highly contagious bacterial infection such as staphylococcus aureus or streptococcus pyogenes of the superficial layers of the epidermis that mainly affect infants and children. In this condition, the patient generally develops the red sores around the nose and mouth. This diseased condition is increasing and thus it is very important to the healthcare sector.
Global Impetigo Therapeutic Market Dynamics
Drivers
- Increasing R&D Activities
It has been seen that adults and children are mostly affected, but children under the age of two are rarely affected. In research studies conducted over the last three years, S. aureus has resurfaced as the primary cause of crusted impetigo. As the most commonly recovered isolated agent, S. aureus, combined with group A beta-hemolytic streptococci, caused around 80% of the cases. There is the involvement of deeper structures, lymphadenopathy, fever, pharyngitis, infections near the oral cavity, infections on the scalp, or multiple lesions; systemic antimicrobial agents are specified. Thus, it acts as a major driver in the market growth.
- Higher Demand of Antibiotics
Topical antibiotics such as mupirocin, retapamulin, and fusidic acid are widely used to treat this condition. Oral antibiotic therapy can be used when topical therapy becomes ineffective or when impetigo with large bullae is present. Penicillin is not an option, but amoxicillin or clavulanate, cephalexin, clindamycin, dicloxacillin, doxycycline, minocycline, trimethoprim, and macrolides are. Topical antibiotics, systemic antibiotics, and topical disinfectants are all the possible options for treating impetigo. This boosts the market growth.
Opportunities
- Increase in Smoking and Lifestyle Changes
Cigarette smoking is one of the leading cause of preventable disease and death in the U.S. It accounts for more than 480,000 deaths every year. In addition to this, the lifestyle changes that are attained by today’s population such as unhealthy lifestyle, poor diet, stress and many such factors altogether contribute to the developing opportunities of the market.
- Higher Demand of Penicillin
The rising demand of penicillin creates more opportunities for the market growth. For instance, in 2017 it has been witnessed that penicillin segment dominated the global impetigo treatment market because of the high preference by the physicians. Penicillin-like antibiotics segment tailed the penicillin segment and accounted for more than 15% of the global share, in terms of value.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to perform these treatments could limit the growth of the global impetigo therapeutic market over a forecast period.
- High Cost
The huge expenditure required for the treatment processes surely hamper the market growth. Several market players make huge investment in installing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.
This global impetigo therapeutic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global impetigo therapeutic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Impetigo Therapeutic Market
COVID-19 has left a major global public health crisis that has impacted practically every market sector. Its long-term consequences are expected to boost the industry growth during the forecast period.
The load on healthcare facilities and professionals was increasing with the rapid surge in patient numbers. Many hospitals have decided to cancel or postpone procedures. The pandemic had a mixed influence on the dilated cardiomyopathy market. The pandemic has put a strain on the treatment procedures in general. As a result of the lockdown and travel restrictions, the number of hospitals has decreased and countless drives have been cancelled around the world.
Global Impetigo Therapeutic Market Scope
The global impetigo therapeutic market is segmented on the basis of route of administrtaion, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Cephalosporins
- Fusidane
- Lincosamide
- Penicillin
- Penicillin-Like Antibiotics
- Others
Route of Administrtaion
- Oral
- Inhalation
- Intranasal
- Others
End-User
- Hospitals
- Research Institutes
- Specialty Clinics
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Impetigo Therapeutic Market Regional Analysis/Insights
The global impetigo therapeutic market is analyzed and market size insights and trends are provided by route of administrtaion, treatment, distribution channel and end-user as referenced above.
The major countries covered in the global impetigo therapeutic market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market in the forecast period due to the high-income of the countries, favorable reimbursement and advanced healthcare facilities.
Asia-Pacific is expected to grow during the forecast period due to the increase government initiatives and presence of generic companies.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Impetigo Therapeutic Market Share Analysis
The global impetigo therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global impetigo therapeutic market.
Key players operating in the global impetigo therapeutic market include:
- Alexion Pharmaceuticals, Inc. (U.S.)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- Vertex Pharmaceuticals Incorporated (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Amgen Inc. (U.S.)
- Jazz Pharmaceuticals, Inc. (U.K.)
- Pfizer Inc (U.S.)
- PerkinElmer Inc (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Abbvie Inc. (U.S.)
- Zydus Group (India)
- Wockhardt (India)
- Lannett (U.S.)
- Sun Pharmaceuticals Industries Ltd. (India)
- Amneal Pharmaceuticals LLC. (U.K.)
SKU-